Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5330242 | 0.97 | TSHR (0.53) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL17372607 | 0.97 | TSHR (0.53) | TSHRTHRBLMNASLC22A1DNM1 | |
| SCHEMBL116897 | 0.96 | TSHR (0.50) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Phosphine SCHEMBL23300907 | 0.93 | TSHR (0.47) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Hexane SCHEMBL29124909 | 0.89 | TSHR (0.58) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Hexane SCHEMBL27826796 | 0.89 | TSHR (0.58) | TSHRTHRBLMNASLC22A1SLC22A2 | |
| Undecane SCHEMBL28453375 | 0.85 | TSHR (0.67) | TSHRTHRBLMNASLC22A1DNM1 | |
| Octane SCHEMBL27625 | 0.85 | TSHR (0.67) | TSHRTHRBLMNASLC22A1DNM1 | |
| Heptane SCHEMBL28458543 | 0.85 | TSHR (0.67) | TSHRTHRBLMNASLC22A1DNM1 | |
| Octane SCHEMBL27624 | 0.85 | TSHR (0.67) | TSHRTHRBLMNASLC22A1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2173716-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | Sanofi-Aventis (FR) | 2010-04-14 | — | — | EP | claimed |
| WO-2009003590-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH HETEROARYL TOSYLATES AND HETEROARYL BENZENESULFONATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | claimed |
| CN-112262200-B | Liquid-crystalline medium | 默克专利股份有限公司 | 2024-09-06 | — | — | CN | disclosed |
| EP-3927685-A1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI Industries Ltd. (IN) | 2021-12-29 | — | — | EP | disclosed |
| EP-3066108-A1 | 4-{4-[(1 E)-4-(2,9-DIAZASPIRO[5.5]UNDEC-2-YL)BUT-1 -EN-1 -YL]-2-METHYLBENZYL}-5-(PROPAN-2-YL)-1 H-PYRAZOL-3-YL BETA-D- GLUCOPYRANOSIDE ACETATE | Eli Lilly and Company (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3010902-A1 | SUBSTITUTED BENZYLPYRAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-27 | — | — | EP | disclosed |
| EP-3010904-A1 | SUBSTITUTED BENZYLPYRAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-27 | — | — | EP | disclosed |
| WO-2015069541-A1 | 4-{4-[(1 E)-4-(2,9-DIAZASPIRO[5.5]UNDEC-2-YL)BUT-1 -EN-1 -YL]-2-METHYLBENZYL}-5-(PROPAN-2-YL)-1 H-PYRAZOL-3-YL BETA-D- GLUCOPYRANOSIDE ACETATE | ELI LILLY AND COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
| EP-2847180-A1 | SUBSTITUTED CYCLOALKENOPYRAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2015-03-18 | — | — | EP | disclosed |
| WO-2014202590-A1 | SUBSTITUTED BENZYLPYRAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014202583-A1 | SUBSTITUTED BENZYLPYRAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-24 | — | — | WO | disclosed |
| EP-2802212-A1 | HERBICIDAL ISOXAZOLO[5,4-B]PYRIDINES | BASF SE (DE) | 2014-11-19 | — | — | EP | disclosed |
| EP-2794596-A1 | SUBSTITUTED BENZYLPYRAZOLES | Bayer Intellectual Property GmbH (DE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013167698-A1 | SUBSTITUTED CYCLOALKENOPYRAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-14 | — | — | WO | disclosed |
| WO-2013104561-A1 | HERBICIDAL ISOXAZOLO[5,4-B]PYRIDINES | BASF SE (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013092512-A1 | SUBSTITUTED BENZYLPYRAZOLES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2012170693-A1 | MATERIALS FOR BATTERY ELECTROLYTES AND METHODS FOR USE | WILDCAT DISCOVERY TECHNOLOGIES, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2010015586-A2 | 2,3,4,7-TETRAHYDRO-INDOLO[2,3-C]QUINOLINE COMPOUNDS | NYCOMED GMBH (DE) | 2010-02-11 | — | — | WO | disclosed |
| EP-2049535-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008016184-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |